Search company, investor...

Founded Year



Series D - II | Alive

Total Raised




Last Raised

$150M | 2 yrs ago



About Ro

Ro operates as a direct-to-patient healthcare company. The company offers a range of healthcare services including telehealth consultations, in-home care, diagnostics, labs, and pharmacy services, all facilitated through its integrated platform. Ro primarily serves the healthcare industry. Ro was formerly known as Roman. It was founded in 2017 and is based in New York, New York.

Headquarters Location

116 West 23rd Street 4th Floor

New York, New York, 10011,

United States



ESPs containing Ro

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Digital Pharmacy Tech

The direct-to-consumer (D2C) prescription dermatology services market offers a convenient and accessible way for individuals to access prescription medications and dermatological treatments directly from the comfort of their homes. These services utilize online platforms and telemedicine to connect patients with licensed dermatologists who can diagnose conditions, prescribe medications, and provid…

Ro named as Leader among 7 other companies, including Hims, Skin + Me, and Curology.

Ro's Products & Differentiators

    Roman / Rory / Plenity / Zero

    Ro first started with three digital health clinics to offer patients end-to-end telehealth treatment for over 20 conditions. Roman which offers treatments for men’s health conditions from sexual health, to hair loss to daily vitamin supplements. Rory, a clinic for women offering treatments for conditions from skincare to menopause to sexual wellness. And Zero, a clinic to help patients quit smoking. Ro also offers Plenity, an offering that provides patients with safe and effective options to manage their weight and tackle obesity.


Expert Collections containing Ro

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ro is included in 7 Expert Collections, including E-Commerce.



10,700 items

Companies that sell goods online (B2C), or enable the selling of goods online via tech solutions (B2B).


Unicorns- Billion Dollar Startups

1,229 items


Digital Health 50

300 items

The most promising digital health startups transforming the healthcare industry


Tech IPO Pipeline

539 items

Track and capture company information and workflow.


Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.



2,856 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Ro Patents

Ro has filed 1 patent.

The 3 most popular patent topics include:

  • engine technology
  • engines
  • exhaust systems
patents chart

Application Date

Grant Date


Related Topics



Sensors, Engine technology, Radial engines, Engines, Exhaust systems


Application Date


Grant Date


Related Topics

Sensors, Engine technology, Radial engines, Engines, Exhaust systems



Latest Ro News

09:00 ET Zepbound™ (Tirzepatide) Now Available Through Ro Body Program

Dec 13, 2023

News provided by Share this article Share toX Patients can explore the latest weight loss medications, understand their coverage and get comprehensive, high-quality care all in one platform NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Ro , the leading direct-to-patient healthcare company, announced today it has expanded its Body Program offering with the launch of Zepbound™ (tirzepatide) injection, the latest FDA-approved weight loss treatment from Eli Lilly and Company. Now, patients can come to Ro to access a broader range of weight loss treatment options based on their goals, insurance, budget, and a licensed provider's assessment. Each patient's Body Program journey is supported by personalized provider care, diagnostic testing, nurse coaching, and education. In a 72-week clinical trial, Zepbound helped people without diabetes lose an average of 48 pounds, or about 20% of their body weight, when they paired the highest maintenance dose with diet and exercise changes (vs 3% with diet and exercise alone). Patients can work with their provider to determine if treatment is appropriate after completing an Online Visit and lab testing via Quest Diagnostics or Ro's at-home collection kit. "The possibilities of a world with Zepbound cannot be understated. Hopefully, with more options and more competition, we'll see expanded coverage of these innovative treatments and increased access for patients." said Zachariah Reitano, co-founder and CEO of Ro. Launched in January 2023, Ro's Body Program has since grown to be the most comprehensive, high-quality weight loss offering available via telehealth, with additional medications and new tools to help patients reach their goals. This expansion includes: Expanded GLP-1/GIP formulary to medication options that include Wegovy, Ozempic, Saxenda and now, Zepbound. Integrated benefits verification to help patients understand their insurance coverage at the beginning and throughout their journey; Automated side effect tracking to help patients communicate with their care team when additional support is needed. This data empowers Ro-affiliated providers to best support patients as they titrate medications; Integrated AI learning models to perform clerical tasks and give providers additional leverage to spend more time with patients and less on manual, administrative tasks; Integrated with Apple Health to enable patients to share their weight loss data with their provider automatically; and more. "Zepbound is poised to be the most impactful anti-obesity medication we've seen so far in our lifetime. In the Body Program, we're pairing access to Zepbound and other effective medication options conveniently alongside everything a patient needs to start their treatment and at each step in their care journey," said Dr. Melynda Barnes, Chief Medical Officer of Ro. "Through Ro, patients can connect with a provider to evaluate all their options for GLP-1 treatment, understand their insurance coverage, and access ongoing, personalized provider care and coaching." To learn more about the Ro Body Program, click here . To see more safety information for Zepbound, including a Boxed Warning, click here or see below. About Ro Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer telehealth, diagnostics, labs, and pharmacy services nationwide. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients in nearly every single county in the United States, including 98% of primary care deserts. Visit  for more information. Important Safety Information, including boxed warning Zepbound (tirzepatide) injection may have serious side effects. Do not use if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In rodents, Zepbound causes thyroid C-cell tumors and its impact in humans is unknown. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. Zepbound is a prescription medicine for patients with obesity (BMI ≥30) or overweight (BMI ≥27) who also have weight-related medical problems, to help them lose weight. Zepbound should not be used in combination with other tirzepatide-containing products or other GLP-1s. The safety and efficacy of coadministration with other products for weight management have not been established. Zepbound has not been studied in patients with a history of pancreatitis. Zepbound may cause serious side effects, including: Severe Gastrointestinal Disease: Zepbound is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe. Zepbound isn't recommended in patients with severe gastrointestinal disease. Acute Kidney Injury: Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe. Drink plenty of water to help reduce chance of dehydration. Acute Gallbladder Disease: Zepbound, other GLP-1 receptor agonists, and weight loss are associated with an increased chance of acute gallbladder disease. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools. Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting. Allergic Reactions: Stop using Zepbound right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy. Do not use Zepbound if you have a known allergic reaction to tirzepatide. Low Blood Sugar (Hypoglycemia): Zepbound can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat. Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Tell your provider right away if you experience changes in vision. Suicidal Behavior and Ideation: Call your healthcare provider right away if you have any mental health changes that are new, worse, or worry you, like sudden changes in your mood, behaviors, thoughts, or feelings. Never Share a Pen: Pen-sharing poses a risk of infection. Tell your provider if you are pregnant or planning to become pregnant If you are pregnant: Zepbound should not be used during pregnancy. If you are a female of reproductive potential: Zepbound may reduce the efficacy of oral hormonal contraceptives. Switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose escalation until you reach a maintenance dose. The most common side effects of Zepbound are: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. You are encouraged to report negative side effects of prescription products: Contact FDA MedWatch at 1-800-FDA-1088 or visit These are not all the side effects of Zepbound. For complete information, including boxed warning, see Important Safety Information:

Ro Frequently Asked Questions (FAQ)

  • When was Ro founded?

    Ro was founded in 2017.

  • Where is Ro's headquarters?

    Ro's headquarters is located at 116 West 23rd Street, New York.

  • What is Ro's latest funding round?

    Ro's latest funding round is Series D - II.

  • How much did Ro raise?

    Ro raised a total of $1.027B.

  • Who are the investors of Ro?

    Investors of Ro include General Catalyst, FirstMark Capital, Initialized Capital, BoxGroup, The Chernin Group and 27 more.

  • Who are Ro's competitors?

    Competitors of Ro include The Pill Club, Simple Health, Wyndly, Diri Care, Noula Health and 7 more.

  • What products does Ro offer?

    Ro's products include Roman / Rory / Plenity / Zero and 4 more.


Compare Ro to Competitors


Numan offers a digital platform for men's health. It helps to promote accessible medical remedies for erectile dysfunction, hair loss, weight loss, low testosterone, and other diseases. It was founded in 2018 and is based in London, United Kingdom.

Pandia Health Logo
Pandia Health

Pandia Health is a company focused on women's health, specifically in the pharmaceutical industry. The company offers services such as online consultations, prescription fulfillment, and delivery of birth control medications. These services are primarily targeted towards the healthcare industry. It was founded in 2016 and is based in Sunnyvale, California.

Thirty Madison Logo
Thirty Madison

Thirty Madison provides virtual-first healthcare services, providing accessible and effective treatments for individuals with ongoing conditions. Its primary market is the healthcare industry. The company was founded in 2017 and is based in New York, New York.


Maximus operates as a consumer health preoperational company. It provides men with content, community, and clinical support. The company offers prescription testosterone medications to consumers. It was formerly known as Actualize. The company was founded in 2020 and is based in Santa Monica, California.

Bluechew Logo

Bluechew is a telemedicine company focused on the healthcare sector. The company offers chewable tablets of Sildenafil, Tadalafil, and Vardenafil, which are used for the treatment of erectile dysfunction symptoms. The company primarily serves men who are unable to tolerate commercially available pills, do not want an in-person doctor's visit, and want to have an increased chance of stronger and longer-lasting erections. It was founded in 2014 and is based in Chicago, Illinois.


ASYSTEM is a company focused on the creation of science-forward supplements in the health sector. The company's main offerings include supplements designed for active lifestyles, with a focus on efficacy and convenience. These products are backed by clinical ingredients and third-party clinical trials. It was founded in 2018 and is based in Venice, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.